Capricor Stock Plunges 58% Thursday After FDA Panel Votes 9-3 Against Deramiocel; Piper Sandler Slashes Target to $2
According to The Fly, Capricor Therapeutics (CAPR) plunged 58% in pre-market trading Thursday after an FDA advisory committee voted 9-3 that the company had not provided substantial evidence that Deramiocel effectively treats cardiomyopathy in Duchenne muscular dystrophy.
Piper Sandler downgraded C
GateNews·24m ago
